Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Consumers and healthcare providers should stop using this product immediately. Contact Fagron Compounding Services or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Fagron Compounding Services recalls
Be the first to know. Free instant alerts to your inbox.
norepinephrine Bitartrate,16mg per 250mL 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5026-02. Reason: Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port. Classification: Class II. Quantity: 25,260 bags. Distribution: Nationwide in the U.S.A.
Not sure what to do next? Our guide walks you through the process step by step.
Read: How to Get Refunds and ReplacementsGet instant alerts for recalls that affect you. Free forever.
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Fagron Compounding Services recalled 34,260 bags of Vancomycin HCI Injection across the United States. The recall cites lack of sterility assurance and a blue Break-Off-Part that could detach from the administration port. Healthcare providers and patients should stop using the product immediately and follow manufacturer guidance.
Fagron Compounding Services is recalling 11,680 bags of Vancomycin HCl 1 g in 250 mL 0.9% Sodium Chloride Injection. The recall is nationwide in the United States. The blue break-off part could detach from the administration port, raising sterility concerns. Stop using immediately and contact the provider for guidance.
Fagron Compounding Services recalled 5,140 bags of norepinephrine Bitartrate injection due to lack of sterility assurance. A blue Break-Off-Part could detach from the administration port. The recall covers nationwide distribution in the U.S. Consumers should stop use and contact providers for guidance.
Fagron Compounding Services recalled 2,980 syringes of a topical ophthalmic solution on November 20, 2025. The recall stems from an incorrect product formulation that could pose health risks. Consumers should stop using the product immediately and contact their healthcare provider for guidance.
Fagron Compounding Services recalls 109,320 sterile single-dose bevacizumab syringes nationwide due to lack of assurance of sterility. Healthcare providers and patients should stop using the product immediately. Contact Fagron Compounding Services or a healthcare provider for guidance. The recall was issued on 2025-08-29 and remains active as of 2025-09-24.